A phase II trial has shown promising results in significantly reducing BPD among infants who received treatment with recombinant human insulin-like growth factor 1 combined with its binding protein (rhIGF-1/rhIGFBP-3) [175]. This evidence concerns the gene IGF1 and bronchopulmonary dysplasia.